



PATENT
Docket No. 2026-4116US2

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s) : Bukh, et al

Serial No. : 09/084,691 Group Art Unit: 1648

Filed : May 26, 1998 Examiner: Zeman, M.

For : NUCLEOTIDE AND DEDUCED AMINO ACID SEQUENCES OF
THE ENVELOPE 1 AND CORE GENES OF ISOLATES OF
HEPATITIS C VIRUS AND THE USE OF REAGENTS DERIVED
FROM THESE SEQUENCES IN DIAGNOSTIC METHODS AND
VACCINES

#15
meda
9/7/01

Commissioner for Patents
Washington, D.C. 20231

STATEMENT UNDER 37 C.F.R. §1.821(f) OR §1.825(b)

Sir:

I hereby certify that:

- [] The paper Sequence Listing and computer readable form of the Sequence Listing submitted herewith are identical (37 C.F.R. §1.821(f)).
- [X] The substitute paper Sequence Listing and substitute computer readable form of the Sequence Listing submitted herewith are identical. No new matter is included. (37 C.F.R. §1.825(b)).

Respectfully submitted,
MORGAN & FINNEGAN, L.L.P.

Date: August 30, 2001

By: William S. Feiler
William S. Feiler
Registration No. 26,728

CORRESPONDENCE ADDRESS:

MORGAN & FINNEGAN, L.L.P.
345 Park Avenue
New York, New York 10154-0053
(212) 758-4800 (Telephone)
(212) 751-6849 (Facsimile)



Docket No. 2026-4116US2

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s) : Bukh, et al

Serial No. : 09/084,691

Group Art Unit: 1648

Filed : May 26, 1998

Examiner: Zeman, M.

For : NUCLEOTIDE AND DEDUCED AMINO ACID SEQUENCES OF
THE ENVELOPE 1 AND CORE GENES OF ISOLATES OF
HEPATITIS C VIRUS AND THE USE OF REAGENTS DERIVED
FROM THESE SEQUENCES IN DIAGNOSTIC METHODS AND
VACCINES

Commissioner for Patents
Washington, D.C. 20231

**RESPONSE TO NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT
APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID
SEQUENCE DISCLOSURES**

Sir:

In response to the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures mailed August 1, 2001, applicant respectfully submits herewith a substitute paper sequence listing; Statement Under 37 CFR 1.825(b); and a substitute computer readable form of the Sequence Listing in replacement of the sequence listing now on file. No new matter is included.

The errors set forth in the Raw Sequence Listing Error Report have been corrected.

This response is timely filed. The Commissioner is hereby authorized to charge any additional fees which may be required by this paper or credit any overpayment to Deposit Account No. 13-4500. Order No. 2026-4116US2. A DUPLICATE COPY OF THIS SHEET IS ATTACHED.

Respectfully submitted,
MORGAN & FINNEGAN, L.L.P.

Date: August 30, 2001

By: _____

William S. Feiler
William S. Feiler

Registration No. 26,728

CORRESPONDENCE ADDRESS:

MORGAN & FINNEGAN, L.L.P.
345 Park Avenue
New York, New York 10154-0053
(212) 758-4800 (Telephone)
(212) 751-6849 (Facsimile)